Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorComitè d’Avaluació de Medicaments d’Ús Hospitalari (CAMUH)
dc.date.accessioned2014-09-30T12:01:08Z
dc.date.available2014-09-30T12:01:08Z
dc.date.issued2013-01
dc.identifier.citationComitè d'Avaluació de Medicaments d'Utilització Hospitalària (CAMUH). Belimumab (Benlysta®) per al tractament del lupus eritematós sistèmic. Barcelona: Agència d‟Informació, Avaluació i Qualitat en Salut; 2013.
dc.identifier.otherCT;04/2013
dc.identifier.urihttp://hdl.handle.net/11351/846
dc.descriptionSystemic Lupus Erythematosus; Belimumab; Clinical Trial
dc.description.abstractSystemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease of unknown etiology with multisystem involvement. The main organs affected are the skin, joints, kidneys, lungs, nervous system and blood, among others, with varying severity. There is currently no treatment or cure definitive etiologic LES, so treatment is aimed at manifestations of the same disease. The overall objective of treatment is to control the disease activity and prevent as far as possible outbreaks. Belimumab is a human monoclonal antibody that binds specifically to the soluble form of the protein stimulating human B cells (Blyss) blocking the binding of the receptor to its respective B cells was approved by the Agency European Medicines July 2011 as adjunctive therapy in adult patients with SLE active with positive autoantibodies with a high degree of disease activity (p. ex. antiDNAdc positive and low complement) despite standard treatment. Objective: To review the efficacy, safety and efficiency in the belimumab treatment of SLE in adults compared to any alternative treatment, including placebo.
dc.language.isocat
dc.publisherAgència d’Informació, Avaluació i Qualitat en Salut de Cataluya
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceScientia
dc.subjectLupus eritematós - Tractament
dc.subjectPell - Malalties
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshLupus Erythematosus, Systemic
dc.subject.meshSkin Diseases
dc.subject.meshPharmaceutical Preparations
dc.titleBelimumab (Benlysta®) per al tractament del lupus eritematós sistèmic
dc.typeinfo:eu-repo/semantics/report
dc.identifier.dlB. 21487-2013
dc.subject.decslupus eritematoso sistémico
dc.subject.decsenfermedades de la piel
dc.subject.decspreparados farmacéuticos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record